Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA) ROC %: 0.00% (As of . 20)


XTUN:SIPHA Societe des Industries Pharmaceutiques de Tunisie-S I PHA T XTUN:SIPHA
12 GF Score
Price TND4.01
! 1 Warning Sign
View Full Analysis

What is Societe des Industries Pharmaceutiques de Tunisie-S I PHA T ROC %?

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T XTUN:SIPHA 12 ROC % is 0.00% as of . 20. GuruFocus rates XTUN:SIPHA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's annualized return on capital (ROC %) for the quarter that ended in . 20 was 0.00%.

As of today (2026-06-26), Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's WACC % is 0.00%. Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's ROC % is 0.00% (calculated using TTM income statement data). Societe des Industries Pharmaceutiques de Tunisie-S I PHA T earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T  (XTUN:SIPHA) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's WACC % is 0.00%. Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's ROC % is 0.00% (calculated using TTM income statement data). Societe des Industries Pharmaceutiques de Tunisie-S I PHA T earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T ROC % Related Terms

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T ROC % Historical Data

* Premium members only.

The historical data trend for Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T ROC % Chart

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Annual Data
Trend
ROC %

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Semi-Annual Data
ROC %
XTUN:SIPHA
12GF Score
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T XTUN:SIPHA
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T ROC % Calculation

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's annualized Return on Capital (ROC %) for the fiscal year that ended in . 20 is calculated as:

ROC % (A: . 20 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: . 20 ) + Invested Capital (A: . 20 ))/ count )
= * ( 1 - % )/( ( + )/ )
=/
= %

where

Invested Capital(A: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

Invested Capital(A: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's annualized Return on Capital (ROC %) for the quarter that ended in . 20 is calculated as:

ROC % (Q: . 20 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: . 20 ) + Invested Capital (Q: . 20 ))/ count )
= * ( 1 - % )/( ( + )/ )
=/
= %

where

Invested Capital(Q: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

Invested Capital(Q: . 20 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
= - - ( - max(0, - +))
=

Note: The Operating Income data used here is one times the annual (. 20) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of 0.00% mean?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA) has a ROC % of 0.00% as of . 20. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Societe des Industries Pharmaceutiques de Tunisie-S I PHA T and its competitors.
Is Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's ROC % too high?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's current ROC % is 0.00%. Overall, Societe des Industries Pharmaceutiques de Tunisie-S I PHA T has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's ROC % compare to BIEI and PTXTQ?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's ROC % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median ROC % is 4.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Drug Manufacturers company?
The median ROC % among Drug Manufacturers companies is 4.44, based on 985 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Societe des Industries Pharmaceutiques de Tunisie-S I PHA T and its competitors. For the Drug Manufacturers industry, the median ROC % is 4.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's current ROC % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Societe des Industries Pharmaceutiques de Tunisie-S I PHA T stock overvalued right now?
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA) has a current ROC % of 0.00%. The current ROC % is 0.00%. Societe des Industries Pharmaceutiques de Tunisie-S I PHA T's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Societe des Industries Pharmaceutiques de Tunisie-S I PHA T (XTUN:SIPHA), the current ROC % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Societe des Industries Pharmaceutiques de Tunisie-S I PHA T Business Description

Address Fondouk Choucha, Ben Arous, TUN, 2013
Societe des Industries Pharmaceutiques de Tunisie-S I PHA T is a Tunisia-based company mainly engaged in manufacturing and distributing medicines and drugs. The company also has its own research and development process to develop generic drugs. It offers pharmaceutical, dietary, hygiene, and cosmetic products in dry, liquid and pasty forms.
12GF Score

Get the complete analysis for XTUN:SIPHA

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

TND4.01
Price